NEWS: AUGUST 2005

-08/05/2005-

Advanced Life Sciences Holdings Inc. goes IPO. To read article click here.

Johnson & Johnson limits use of Natrecor. To read article click here.

-08/04/2005-

Telik Inc. announces second quarter 2005 financial results. To read article click here.

Genelabs Technologies Inc. advances its non-nucleoside compound GL60667 for Hepatitis C virus (HCV) into preclinical development. To read article click here.

-08/03/2005-

FDA approves Novartis Pharmaceuticals Corporation's Diovan® (valsartan) for post-heart attack treatment. To read article click here.

Protein Design Labs Inc. and Biogen Idec sign agreement for the development of three antibodies. To read article click here.

-08/02/2005-

Press Release: Cancer Research Yields Promising Results. To read press release click here.

FDA grants fast-track status to Panitumumab for colon cancer treatment. To read article click here.

-08/01/2005-

Press Release: Frost & Sullivan Seminar to Assess Successful Entry Strategies for Chinese Healthcare Market. To read press release click here.

Qiagen NV to acquire LumiCyte Inc. and SuNyx GmbH. To read article click here.

FDA grants fast track status to Abgenix and Amgen's Panitumumab for metastatic colorectal cancer. To read article click here.

FDA approves Pfizer Inc.'s COX-2 inhibitor Celebrex (celecoxib) for symptoms associated with ankylosing spondylitis. To read article click here.

Human Genome Sciences Inc. received $7 million from GlaxoSmithKline for GSK716155 (Albugon) for diabetes treatment. To read article click here.